Business Description
![Avalo Therapeutics Inc Avalo Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000AXS2.png?14)
Avalo Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US15671L1098
Description
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 202.16 | |||||
Equity-to-Asset | -0.82 | |||||
Debt-to-Equity | -0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -9.88 | |||||
Beneish M-Score | -5.7 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -71.3 | |||||
3-Year EBITDA Growth Rate | 62.9 | |||||
3-Year EPS without NRI Growth Rate | 60.7 | |||||
3-Year FCF Growth Rate | 60.3 | |||||
3-Year Book Growth Rate | -21.9 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 29.48 | |||||
9-Day RSI | 41.61 | |||||
14-Day RSI | 46.08 | |||||
6-1 Month Momentum % | 44.94 | |||||
12-1 Month Momentum % | -86.41 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.52 | |||||
Quick Ratio | 0.52 | |||||
Cash Ratio | 0.51 | |||||
Days Inventory | 10.6 | |||||
Days Sales Outstanding | 9.57 | |||||
Days Payable | 945.09 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 14.5 | |||||
Shareholder Yield % | -1099.89 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 54.9 | |||||
Operating Margin % | -1371.03 | |||||
Net Margin % | -9853.72 | |||||
FCF Margin % | -1850.34 | |||||
ROA % | -304.7 | |||||
ROIC % | -31.71 | |||||
ROC (Joel Greenblatt) % | -1155.28 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.89 | |||||
EV-to-EBIT | 3.54 | |||||
EV-to-EBITDA | 3.56 | |||||
EV-to-Revenue | -59.41 | |||||
EV-to-Forward-Revenue | 0.3 | |||||
EV-to-FCF | 3.21 | |||||
Earnings Yield (Greenblatt) % | 28.25 | |||||
FCF Yield % | -222.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AVTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Avalo Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 1.45 | ||
EPS (TTM) ($) | -319.188 | ||
Beta | 0.87 | ||
Volatility % | 424.87 | ||
14-Day RSI | 46.08 | ||
14-Day ATR ($) | 1.159104 | ||
20-Day SMA ($) | 12.0155 | ||
12-1 Month Momentum % | -86.41 | ||
52-Week Range ($) | 3.9501 - 95.519999 | ||
Shares Outstanding (Mil) | 1.03 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Avalo Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Avalo Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Avalo Therapeutics Inc Frequently Asked Questions
What is Avalo Therapeutics Inc(AVTX)'s stock price today?
The current price of AVTX is $11.64. The 52 week high of AVTX is $95.52 and 52 week low is $3.95.
When is next earnings date of Avalo Therapeutics Inc(AVTX)?
The next earnings date of Avalo Therapeutics Inc(AVTX) is 2024-08-02 Est..
Does Avalo Therapeutics Inc(AVTX) pay dividends? If so, how much?
Avalo Therapeutics Inc(AVTX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |